Skip to main content
SpringerLink
Log in

The efficacy of probucol combined with hydration in preventing contrast-induced nephropathy in patients with coronary heart disease undergoing percutaneous coronary intervention: a multicenter, prospective, randomized controlled study

  • Nephrology - Original Paper
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Purpose

To investigate the preventive effect of probucol combined with hydration on contrast-induced nephropathy (CIN) in patients with coronary heart disease undergoing percutaneous coronary intervention (PCI).

Methods

A total of 641 patients undergoing PCI were randomly assigned to either a probucol group (probucol 500 mg twice daily and hydration; n = 321) or a control group (hydration only; n = 320). The primary endpoint was the incidence of CIN, defined as an increase in serum creatinine (Scr) by ≥ 44.2 μmol/L or ≥ 25% within 72 h after the administration of contrast agent. Secondary endpoints were changes in Scr, cystatin-C (Cys-C), creatinine clearance rate (Ccr), C-reactive protein (CRP), superoxide dismutase (SOD), and glutathione (GSH) within 72 h, and major adverse events during hospitalization or the 14-day follow-up period.

Results

The incidence of CIN was 4.0% (13/321) in the probucol group and 10.9% (35/320) in the control group. The probucol group had lower Cys-C and higher Ccr at 48 and 72 h after PCI compared with the control group. At 48 and 72 h following the operation, Cys-C and CRP were lower in the probucol group compared with the control group, but Ccr, SOD, and GSH were higher. There were no differences in the incidence of major adverse events during hospitalization or the 14-day follow-up between the groups. Multivariate logistic regression analysis showed that probucol was an independent protective factor for CIN.

Conclusions

Probucol combined with hydration more effectively decreased the incidence of CIN in patients with coronary heart disease undergoing PCI compared with hydration alone.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Wang J, Ai X, Li L, Gao Y, Sun N, Li C, Sun W (2017) Alprostadil protects type 2 diabetes mellitus patients treated with metformin from contrast-induced nephropathy. Int Urol Nephrol. doi:10.1007/s11255-017-1639-2

    Google Scholar 

  2. Nash K, Hafeez A, Hou S (2002) Hospital-acquired renal insufficiency. Am J Kidney Dis 39(5):930–936

    Article  PubMed  Google Scholar 

  3. Firouzi A, Maadani M, Kiani R, Shakerian F, Sanati HR, Zahedmehr A, Nabavi S, Heidarali M (2015) Intravenous magnesium sulfate: new method in prevention of contrast-induced nephropathy in primary percutaneous coronary intervention. Int Urol Nephrol 47(3):521–525

    Article  CAS  PubMed  Google Scholar 

  4. Bei W, Li H, Lin K (2017) Post-Hoc Study: intravenous Hydration Treatment in Chinese Patients with High Risk of Contrast-Induced Nephropathy Following Percutaneous Coronary Intervention. Sci Rep 7(3):45023

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Song T, Song M, Ge Z (2017) Comparison of the nephrotoxic effects of iodixanol versus iohexol in patients with chronic heart failure undergoing coronary angiography or angioplasty. J Interv Cardiol 30(3):281–285

    Article  PubMed  Google Scholar 

  6. Owen RJ, Hiremath S, Myers A (2014) Canadian Association of Radiologists consensus guidelines for the prevention of contrast-induced nephropathy: update 2012. Can Assoc Radiol J 65(2):96–105

    Article  PubMed  Google Scholar 

  7. Heyman SN, Rosen S, Khamaisi M, Idée JM, Rosenberger C (2010) Reactive oxygen species and the pathogenesis of radio contrast-induced nephropathy. Invest Radio 145(4):188–195

    Article  Google Scholar 

  8. Liu YH, Jiang L, Chen JY, Tan N, Liu Y, He PC (2016) Does N-terminal pro-brain natriuretic peptide add prognostic value to the Mehran risk score for contrast-induced nephropathy and long-term outcomes after primary percutaneous coronary intervention? Int Urol Nephrol 48(10):1675–1682

    Article  CAS  PubMed  Google Scholar 

  9. He P, Kawamura H, Takemoto M, Maezawa Y, Ishikawa T, Ishibashi R, Sakamoto K, Shoji M, Hattori A, YamagaM Ide S, Ide K, Hayashi A, Tokuyama H, KobayashiK Yokote K (2016) Combination ofcilostazol and probucol protected podocytesfromlipopolysaccharide-induced injury by both anti-inflammatory and anti-oxidative mechanisms. J Nephroldoi. doi:10.1007/s40620-016-0361-y

    Google Scholar 

  10. Zhang Q, Chen L, Si Z, Bu H, Narasimhulu CA, Song X, Cui MY, Liu H, Lu T, He G, Parthasarathy S, Cui L, Liu Z, Cui Y (2016) Probucol protects endothelial progenitor cells against oxidized low-density lipoprotein via suppression of reactive oxygen species formation in vivo. Cell Physiol Biochem 39(1):89–101

    Article  PubMed  Google Scholar 

  11. Lee HC, Sheu SH, Liu IH, Lee CC, Hsieh CC, Yen HW, Lai WT, Chang JG (2012) Impact of short-duration administration of N-acetylcysteine, probucol and ascorbic acid on contrast-induced cytotoxicity. J Nephrol 25(1):56–62

    Article  CAS  PubMed  Google Scholar 

  12. Navarese EP, Gurbel PA, Andreotti F, Kołodziejczak MM, Palmer SC, Dias S, Buffon A, Kubica J, Kowalewski M, Jadczyk T, Laskiewicz M, Jędrzejek M, Brockmeyer M, Airoldi F, Ruospo M, De Servi S, Wojakowski W, O’ Connor C, Strippoli GF (2017) Prevention of contrast-induced acute kidney injury in patients undergoing cardiovascular procedures-a systematic review and network meta-analysis. PLoS ONE 12(2):e0168726

    Article  PubMed  PubMed Central  Google Scholar 

  13. Toprak O (2017) Risk markers for contrast-induced nephropathy. Am J Med Sci 334(4):283–290

    Article  Google Scholar 

  14. Su X, Xie X, Liu L, Lv J, Song F, Perkovic V, Zhang H (2017) Comparative effectiveness of 12 treatment strategies for preventing contrast-induced acute kidney injury: a systematic review and Bayesian network meta-analysis. Am J Kidney Dis 69(1):69–77

    Article  CAS  PubMed  Google Scholar 

  15. Pflueger A, Abramowitz D, Calvin AD (2009) Role of oxidative stress in contrast-induced acute kidney injury in diabetes mellitus. Med Sci Monit 15(6):125–136

    Google Scholar 

  16. Liu Y, Tan N, Zhou YL (2012) High-sensitivity C-reactive protein predicts contrast-induced nephropathy after primary percutaneous coronary intervention. J Nephrol 25(3):332–340

    Article  CAS  PubMed  Google Scholar 

  17. Kasai T, Miyauchi K, Kubota N, Kajimoto K, Amano A, Daida H (2012) Probucol therapy improves long-term (> 10-year) survival after complete revascularization: a propensity analysis. Atherosclerosis 220(2):463–469

    Article  CAS  PubMed  Google Scholar 

  18. Liu J, Li M, Lu H, Qiao W, Xi D, Luo T, Xiong H, Guo Z (2015) Effects of probucol on restenosis after percutaneous coronary intervention: a systematic review and meta-analysis. PLoS ONE 10(4):e0124021

    Article  PubMed  PubMed Central  Google Scholar 

  19. Adameova A, Xu YJ, Duhamel TA, Tappia PS, Shan L, Dhalla NS (2009) Anti-atherosclerotic molecules targeting oxidative stress and inflammation. Current Pharm Des 15(27):3094

    Article  CAS  Google Scholar 

  20. Yoshida M, Kimura H, Kyuki K, Ito M (2006) Combined effect of probucol and insulin on renal damage in diabetic rats fed a high cholesterol diet. Eur J Pharmacol 48(1–3):174

    Article  Google Scholar 

  21. Li G, Yin L, Liu T, Zheng X, Xu G, Xu Y, Yuan R, Che J, Liu H, Zhou L, Chen X, He M, Li Y, Wu L, Liu E (2009) Role of probucol in preventing contrast-induced acute kidney injury after coronary interventional procedure. Am J Cardiol 103(4):512

    Article  CAS  PubMed  Google Scholar 

  22. Yin L, Li G, Liu T, Yuan R, Zheng X, Xu G, Xu Y, Che J, Liu X, Ma X, Li F, Liu E, Chen X, Wu L, Fan Z, Ruan Y, He M, Li Y (2013) Probucol for the prevention of cystatin C-based contrast-induced acute kidney injury following primary or urgent angioplasty: a randomized, controlled trial. Int J Cardiol 167(2):426–429

    Article  PubMed  Google Scholar 

  23. Li H, Li X, Ma H, Wang Y, Fu N, Jin D, Cong H (2014) Atorpvastatin combining with probucol: a new way to reduce serum uric acid level during perioperative period of interventional procedure. Sci W J. doi:10.1155/2014/565367

    Google Scholar 

  24. Börekçi A, Gür M, Türkoğlu C, Çaylı M, Selek Ş, KaypaklıO Uçar H, Coşkun M, Şeker T, Koç M, Gökdeniz T, Gözükara MY (2015) Oxidative stress and paraoxonase 1 activity predict contrast-induced nephropathy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Angiology 66(4):339–345

    Article  PubMed  Google Scholar 

  25. Jian-Wei Z, Yu-Jie Z, Shu-Jun C, Qing Y, Shi-Wei Y, Bin N (2014) Impact of preprocedural high-sensitivity C-reactive protein on contrast-induced nephropathy in patients undergoing primary percutaneous coronary intervention. Angiology 65(5):402–407

    Article  PubMed  Google Scholar 

  26. Wang N, Wei RB, Li QP, Yang X, Li P, Huang MJ (2015) Renal Protective Effect of Probucol in Rats with Contrast-Induced Nephropathy and its Underlying Mechanism. Med Sci Monit 21:2886–2892

    Article  PubMed  PubMed Central  Google Scholar 

  27. Yen HW, Lee HC, Lai WT, Sheu SH (2007) Effects of acetylcysteine and probucol on contrast medium-induced depression of intrinsic renal glutathione peroxidase activity in diabetic rats. Arch Med Res 38(3):291–296

    Article  CAS  PubMed  Google Scholar 

  28. Zhu H, Chen X, Cai G, Zheng Y, Liu M (2016) Telmisartan combined with probucol effectively reduces urinary protein in patients with type 2 diabetes: a randomized double-blind placebo-controlled multicenter clinical study. J Diabetes 8(5):677

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This study was funded by a grant from the Tianjin Municipal Health and Family Planning Commission (Grant Number: 14KG124). We thank Alexander Pishief, LLB, BBmedSc, from Liwen Bianji, Edanz Group China (www.liwenbianji.cn/ac), for editing the English text of a draft of this manuscript.

Author information

Authors and Affiliations

  1. Department of Cardiology, Tianjin Chest Hospital, No. 261, Taierzhuang South Road, Jinnan District, Tianjin, 300222, China

    Naikuan Fu, Shicheng Yang, Jing Zhang, Peng Zhang & Hongliang Cong

  2. Tianjin Medical University, Tianjin, China

    Min Liang

  3. Department of Cardiology, Teda International Cardiovascular Hospital, Tianjin, China

    Wenhua Lin

  4. Department of Cardiology, Tianjin Fourth Central Hospital, Tianjin, China

    Fengshi Tian

  5. Department of Cardiology, Tianjin First Central Hospital, Tianjin, China

    Chengzhi Lu

Authors
  1. Naikuan Fu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shicheng Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jing Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Peng Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Min Liang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hongliang Cong
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Wenhua Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Fengshi Tian
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Chengzhi Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jing Zhang.

Ethics declarations

Conflict of interest

The authors declare that they have no conflicts of interest.

Human and animal rights

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fu, N., Yang, S., Zhang, J. et al. The efficacy of probucol combined with hydration in preventing contrast-induced nephropathy in patients with coronary heart disease undergoing percutaneous coronary intervention: a multicenter, prospective, randomized controlled study. Int Urol Nephrol 50, 105–112 (2018). https://doi.org/10.1007/s11255-017-1718-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-017-1718-4

Keywords

Search

Navigation